Showing 1 - 20 results of 1,298 for search '(( status ((small decrease) OR (a decrease)) ) OR ( ai ((larger decrease) OR (marked decrease)) ))', query time: 0.58s Refine Results
  1. 1

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    Flow chart of data screening and analysis. by Yan She (8639796)

    Published 2025
    “…In contrast, the BMD, BV/TV, and Tb.N in the 12-week model group exhibited a modest but non-significant decrease relative to the 9-week model group. …”
  19. 19
  20. 20

    Patient status overview. by Farayi Kaseke (19560197)

    Published 2024
    “…Housing status revealed a protective effect for those residing with parents/relatives (aHR: 0.4, 95% CI: 0.20, 0.64). …”